How Clinical Trials Work and Who is WINNING the Race (FOR NOW) // MAPS, CMPS, MNMD & more

HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).

This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.

In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.

Timestamps:

0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#CompassPathways #CMPS #PsychedelicTherapy

Who’s next in line to Uplist to the Nasdaq? Numinus? Cybin? FieldTrip? ALL of them??
Today, I’ll be covering an article by Jeff Neilson published on The Psychedelic Stock Watch. In this article, Jeff outlines several stocks as contenders for an uplisting.

* Cybin Inc (CAN:CYBN / US:CLXPF) : Cybin is also one of the more successful companies in raising capital, having raised ~CAD$88.8 million (US$70 million) since going public last November and as we have been repeating on this channel, capital is a very important factor for the successful continuation and advancement of clinical trials.

*Field Trip Health (CAN:FTRP / US:FTRPF) : Field Trip Health shares some similarities with Cybin as an uplisting prospect. It has raised even more capital than Cybin, in excess of US$100 million, including its recent CAD$95 million bought deal financing (US$76 million) and Field Trip has also a price target of CAD$8.50 price target from Stifel GMP to its February 2021 high of CAD$8.25.

*Numinus Wellness (CAN:NUMI / US:LKYSF) : Numinus Wellness actually has a stronger following among retail investors than either Cybin or Field Trip. It was second only to MindMed as the volume leader among psychedelic stocks in the 2020 rally. It was also the second-best performer among all of the leading stocks in that rally, generating a 10X return at its 2020 peak.

However, these are not the only psychedelic stocks to peak Jeff Neilson’s eye.
He also mentions:

Mind Cure Health (CAN:MCUR / US:MCURF)
Mydecine Innovations Group (CAN:MYCO / US:MYCOF)
Bright Minds Biosciences (CAN:DRUG / US:BMBIF)
Small Pharma Inc( it hasn’t even started public trading YET)

Timestamps:
0:00 – Intro
1:55 – Cybin ( CYBN / CXPF )
6:13 – Field Trip Health ( FTRP / FTRPF )
9:05 – Numinus Wellness ( NUMI / LKYSF )
11:35 – Mindcure Health
12:08 – Mydecine ( MYCO /MYCOF )
12:34 – Bright Minds Biosciences ( DRUG / BMBIF )
13:10 – Small Pharma Inc.

Link to the article in question: https://psychedelicstockwatch.com/psychedelic-stock-news/the-next-psychedelic-stock-to-uplist-on-the-nasdaq?fbclid=IwAR3CgezfqtNHk0U3_YX5LYHDU2Y34jEFSTdNVGVchsKgR4CdEj58Q-lYcwk
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Canacord: https://thetradingpriest.com/wp-content/uploads/2021/04/ResearchReport-1.pdf
Link to Numinus (NUMI): https://numinus.ca/
Link to Field Trip ( FTRP / FTRPF) : https://www.fieldtriphealth.com/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Cybin #Numi

In today’s episode, we discuss :MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF).

2020 was a wild year for MindMed, with the company IPOing in March, at just over 20c/ share, all prices in American currency. Then, the MindMed stock price shot up to a high of $4.37 in December, only to fall about 30% and consolidate around $3 a share in the new year.

But what will be the main catalysts for MindMed and its stock going forward in 2021? Put another way, what are the events and dates that shareholders and potential investors should circle on their calendars?

In this episode, we are going to talk about several catalysts to look out for
1. MindMed’s Nasdaq uplisting
– When to expect MindMed to join the Nasdaq?
– Is MindMed’s uplisting a sure thing?
-What will happen to MindMed stock if/when the company gets uplisted?

2. Clinical trials wrapping up, and data being released by MindMed
– Important dates MindMed investors should circle in their calendars
3. MindMed’s quarter end financial reporting
4. MindMed conference calls

Unknown Catalysts for Mindmed:
1. Clinical trials expansions
2. Financial agreements

** Also, on the 20th of January, Kevin O’Leary and Jr Rahn went live discussing MindMed. For those who haven’t seen it, Jr mentioned a few extra catalysts we should be looking forward to which we will discuss in our next episode.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://www.prnewswire.com/news-releases/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round-301178915.html

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

So what happened with MindMed (MMED / MNMD) on the day on the NASDAQ uplisting? As we all know, MindMed announced on 23rd of April that the MMEDF stock will uplist on NASDAQ on April 27th under ticker MNMD. for MMED : NEO owners, the stock ticker will remain the same, adjusted to US ER.

Ever since, we all speculated on what will happen to the MindMed stock on April 27 and what will be it’s closing price? On April 26th, the stock price rose to near all time highs and a lot of retail investors thought that on the 27th, the run will continue. MindMed’s move to the Nasdaq was to increase the visibility of its stock in hopes of reaching out to a new group of retail and institutional investors.

Unfortunately, the plan didn’t go so well. While MindMed opened at the previous all time high, the stock dropped throughout the day. MindMed, (MNMD) closed today after its first day on the Nasdaq at: $4.02, down 16%,
most probably due to investors who took some profits, which was one of the scenarios in our previous video on MindMed Nasdaq Uplisting price predictions.

So in this video, I’ll share my thoughts on today’s MMED / MNMD stock events and then discuss the near time future catalysts for MindMed.

Timestamps:
0:00 – Intro
1:27 – Thoughts on MindMed (MNMD) first trading day on NASDAQ
6:05 – MindMed catalyst #1 – Atai’s IPO
7:37 – PSIL ETF coming soon
9:58 – Phase 2a results for MindMed’s Project LUCY
11:38 – Project LUCY starting Phase2b in Q4 this year
12:26 – Completion of Phase 1 Trial for Project Layla (18-MC)
13:08 – Completion of Phase 1 LSD Neutralizer Study

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Links to Clinical trials :

https://clinicaltrials.gov/ct2/results?cond=&term=LSD&cntry=&state=&city=&dist=
https://clinicaltrials.gov/ct2/show/NCT03153579?term=LSD&draw=2&rank=5&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY

https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD&draw=2&rank=6&fbclid=IwAR3fZtlvGX2UAFI0pOkFNANqVpU8ac5pLBTyfwfbd3D4v_1OW61fZLFZGkY

https://mindmed.co/wp-content/uploads/2021/04/MindMed-Corporate-Presentation-4.27.2021.pdf

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MindMedNasdaq #MindMedstock